Skip Nav Destination
Issues
February 2016
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
ISSN 1660-2854
EISSN 1660-2862
In this Issue
Neurodegenerative Diseases 2016, Vol. 16, No. 1-2
Title Page / Table of Contents
Neurodegener Dis (2016) 16 (1-2): 1–4.
https://doi.org/10.1159/000442964
Review
Defining the Genetic Architecture of Alzheimer's Disease: Where Next?
Neurodegener Dis (2016) 16 (1-2): 6–11.
https://doi.org/10.1159/000440841
Tau as the Converging Protein between Chronic Stress and Alzheimer's Disease Synaptic Pathology
Neurodegener Dis (2016) 16 (1-2): 22–25.
https://doi.org/10.1159/000440844
Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies
Neurodegener Dis (2016) 16 (1-2): 26–33.
https://doi.org/10.1159/000441422
Original Paper
Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease
Neurodegener Dis (2016) 16 (1-2): 39–43.
https://doi.org/10.1159/000438925
Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing
Marcus O.W. Grimm; Viola J. Haupenthal; Janine Mett; Christoph P. Stahlmann; Tamara Blümel; Nadine T. Mylonas; Kristina Endres; Heike S. Grimm; Tobias Hartmann
Neurodegener Dis (2016) 16 (1-2): 44–54.
https://doi.org/10.1159/000440839
Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome
Antonella Tramutola; Chiara Lanzillotta; Andrea Arena; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Neurodegener Dis (2016) 16 (1-2): 62–68.
https://doi.org/10.1159/000441419
Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment
Alba Sierra-Rio; Mircea Balasa; Jaume Olives; Anna Antonell; Alex Iranzo; Magda Castellví; Beatriz Bosch; Oriol Grau-Rivera; Guadalupe Fernandez-Villullas; Lorena Rami; Albert Lladó; Raquel Sánchez-Valle; José Luis Molinuevo
Neurodegener Dis (2016) 16 (1-2): 69–76.
https://doi.org/10.1159/000439258
Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations
Camila Orellana; Daniel Ferreira; J.-Sebastian Muehlboeck; Patrizia Mecocci; Bruno Vellas; Magda Tsolaki; Iwona Kłoszewska; Hilkka Soininen; Simon Lovestone; Andrew Simmons; Lars-Olof Wahlund; Eric Westman; for the AddNeuronMed consortium and for the Alzheimer's Disease Neuroimaging Initiative
Neurodegener Dis (2016) 16 (1-2): 77–86.
https://doi.org/10.1159/000442443
Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum
Duygu Tosun; Norbert Schuff; William Jagust; Michael W. Weiner; for the Alzheimer''s Disease Neuroimaging Initiative
Neurodegener Dis (2016) 16 (1-2): 87–94.
https://doi.org/10.1159/000439257
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease
Abraham Fisher; Ilya Bezprozvanny; Lili Wu; Daniel A. Ryskamp; Nira Bar-Ner; Niva Natan; Rachel Brandeis; Hanoch Elkon; Victoria Nahum; Eitan Gershonov; Frank M. LaFerla; Rodrigo Medeiros
Neurodegener Dis (2016) 16 (1-2): 95–110.
https://doi.org/10.1159/000440864
Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?
Marina Boccardi; Daniele Altomare; Clarissa Ferrari; Cristina Festari; Luigi Antelmi; Michela Pievani; Anna Tarallo; Cristina Muscio; Ugo P. Guerra; Barbara Paghera; Alessandro Padovani; Giovanni B. Frisoni; and the INDIA-FBP Working Group
Neurodegener Dis (2016) 16 (1-2): 111–117.
https://doi.org/10.1159/000439255
Brief Communication
Author Index Vol. 16, No. 1-2, 2016
Neurodegener Dis (2016) 16 (1-2): 125.
https://doi.org/10.1159/000442965
Subject Index Vol. 16, No. 1-2, 2016
Neurodegener Dis (2016) 16 (1-2): 126.
https://doi.org/10.1159/000442966
